Overview of Intracameral Drug Delivery Systems in Glaucoma.

Glaucoma is the leading cause of irreversible blindness worldwide, and intraocular pressure (IOP) remains the only proven modifiable risk factor for slowing disease progression. Although topical medications are the standard first-line therapy, their effectiveness is limited by poor adherence and low ocular bioavailability. These limitations have prompted the development of non-topical drug delivery systems (DDSs) that aim to provide consistent long-term IOP control without reliance on patient-administered drops. Among these approaches, intracameral DDSs have received increasing attention for their ability to deliver medication directly to the anterior chamber. This review aims to provide clinicians with an overview of the design, clinical performance, and key considerations of the two FDA-approved intracameral implants, Durysta® (BimSR) and iDose® TR (iDose), as well as investigational devices including ENV515, OTX-TIC, and PA5108. Currently, clinical trials indicate that these devices can achieve sustained reductions in IOP with efficacy comparable to topical prostaglandins (PGA), and real-world studies similarly report reductions in both IOP and medication burden. However, several limitations remain, including concerns about corneal endothelial cell loss (CECL), variability in treatment response among patients with more advanced disease, and the limited availability of long-term safety and durability data. In addition, randomized comparative studies evaluating intracameral DDSs against other glaucoma interventions, such as minimally invasive glaucoma surgery (MIGS), are scarce. Intracameral DDSs represent a developing area within glaucoma management, and further evidence is needed to clarify their long-term safety and their appropriate role within personalized treatment strategies.

• Publication year

  2026

• Venue

  Clinical Ophthalmology

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/opth.s568183PMID 41743462PMCID PMC12931133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostaglandin Intracameral Implants for Ocular Hypertension and Open-Angle Glaucoma

  2025cited by this paper
• Travoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes

  2025influential reference
• Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.

  2025influential reference
• Drug Delivery Systems in Glaucoma- Current Innovations and Future Perspectives.

  2025influential reference
• Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice

  2025cited by this paper
• Travoprost Intracameral Implant: A Review on the Novel Treatment Modality for Open-Angle Glaucoma and Ocular Hypertension

  2024cited by this paper
• Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States

  2024cited by this paper
• Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review

  2024cited by this paper
• The relationship between intraocular pressure and glaucoma: an evolving concept.

  2024cited by this paper
• Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials

  2024cited by this paper
• Sustained Release Therapies with the Prostaglandin Analogues Intracameral Implants

  2024influential reference
• The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study

  2024cited by this paper
• Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.

  2024cited by this paper
• Next generation therapeutics for retinal neurodegenerative diseases.

  2024cited by this paper
• Sustained release ocular drug delivery systems for glaucoma therapy

  2023cited by this paper
• Neuroretinal Rim Response to Transient Intraocular Pressure Challenge Predicts the Extent of Retinal Ganglion Cell Loss in Experimental Glaucoma

  2023cited by this paper
• Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress

  2023cited by this paper
• Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension

  2023cited by this paper
• Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension

  2022cited by this paper
• Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications

  2022cited by this paper
• Topical ocular drug delivery systems: Innovations for an unmet need.

  2022influential reference
• Adherence to Therapy in Glaucoma Treatment—A Review

  2022cited by this paper
• Updates on the Diagnosis and Management of Glaucoma

  2022cited by this paper
• Sustained-release drug delivery systems for the treatment of glaucoma.

  2021cited by this paper
• Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

  2021cited by this paper
• Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).

  2020cited by this paper
• Strategies to prolong the residence time of drug delivery systems on ocular surface.

  2020cited by this paper
• Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial

  2019cited by this paper
• Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues

  2019cited by this paper
• 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients

  2019influential reference
• Polymer‐based carriers for ophthalmic drug delivery

  2018cited by this paper
• Interim Analysis of Low Dose ENV515 Travoprost XR with 11 Month Duration Followed by Dose Escalation and 28 Day Efficacy Evaluation of High Dose ENV515

  2017cited by this paper
• Long-term intraocular Pressure (IOP) control by means of a novel biodegradable intracameral (IC) latanoprost free acid (LFA) implant

  2017cited by this paper
• Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity

  2016cited by this paper
• Design and Development of ENV515 Intraocular Applicator for Intracameral Injections of ENV515 Glaucoma Extended Release (XR) Therapy

  2016cited by this paper
• Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action

  2014cited by this paper
• Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

  2014cited by this paper
• Patient Acceptance and Attitude Toward an Alternative Method of Subconjunctival Injection for the Medical Treatment of Glaucoma

  2013influential reference
• The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

  2002cited by this paper

• No citing papers are available for this paper.